SAT0397 Safety and immunogenicity of 23-valent pneumococcal vaccine in sle patients. (12th June 2018)

• Record Type: Journal Article
• Authors: Tarasova, G.; Belov, B.; Bukhanova, D.; Soloviev, S.; Aseeva, E.; Popkova, T.; Cherkasova, M.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 1061
• Page End: 1061
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.3663
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Immunisation with pneumococcal vaccine is the key prophylactic measure to protect patients with systemic lupus erythematosus (SLE) against severe respiratory infections. Objectives: To study the efficacy and immunogenicity of 23-valent polysaccharide pneumococcal vaccine in SLE pts. Methods: The study included 30 SLE pts, 27 females, 3 males, aged 19–62 y, the follow up (FUP) was 12 mo. Disease activity at vaccination was high – in 1 patient, moderate – in 4 pts, and low – in 20 pts; drug-induced remission – in 5. Therapy: 29 pts were on glucocorticoids (GCs), 23 – on hydroxychloroquine, 14 – on cytostatic (CS) drugs, 9 – on biologic diseases modifying anti rheumatic drugs (bDMARDs): 4 – on rituximab, and 5 – on belimumab. One dose (0, 5 mL) of 23-valent polysaccharide pneumococcal vaccine was administered subcutaneously. Standard clinical examination and lab tests were performed, and vaccine immunogenicity was determined by measuring antibody (AB) levels against Streptococcus pneumoniae (VaccZymeTM PCP IG 2 panels (The Binding Site Ltd, Birmingham, UK)) at control visits. Results: Local injection site reactions of varying intensity were registered in 19 (63, 3%) pts, lasting from 2 to 7 days. One patient developed an immediate hypersensitivity reaction – the Arthus phenomenon-type. All accompanying symptoms completely resolved within 7 days with the intake of antihistaminic drug and local use of GCs. Mean (Me (25, 75 percentiles)) SLEDAI scores for SLE activity prior to and 1 year after vaccination did not differ significantly: 2 (2;4) and 2 (0;4), respectively. Mean values of SLE immunological activity parameters (a-dsDNA, C3 and C4 components of the complement) also did not differ significantly, with a visible trend for a-dsDNA reduction and complement components increase: C3 (0, 86 (0, 81;1.07) and 0, 93 (0, 86;1, 05)); C4 (0, 16 (0, 13;0, 19) and 0, 18 (0, 13;0, 19), respectively. (table 1) Conclusions: Obtained results demonstrate the safety and immunogenicity of 23-valent pneumococcal vaccine in SLE patients during one year FUP. The negative effect of bDMARDs on post-vaccination response was noticed. Future studies of vaccine efficacy and safety are needed in larger SLE populations. Disclosure of Interest: None declared